home / stock / olma / olma news

OLMA News and Press, Olema Pharmaceuticals Inc. From 10/05/22

Stock Information
Company Name: Olema Pharmaceuticals Inc.
Stock Symbol: OLMA
Market: NASDAQ
Website: olema.com
Menu
OLMA OLMA Quote OLMA Short OLMA News OLMA Articles OLMA Message Board
Get OLMA Alerts

News, Short Squeeze, Breakout and More Instantly...
OLMA - Olema Oncology grants stock options for 58.3K shares

Olema Pharmaceuticals ( NASDAQ: OLMA ) said it granted stock options to four new employees to buy a total of 58.3K common shares, effective Oct. 3. The awards were granted under Olema's 2022 Inducement Plan, the company said in an Oct. 4 press release. The stock op...
OLMA - Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

OLMA - SWTX, ALLG and ISPO among mid-day movers

Gainers: Euro Tech Holdings ( CLWT ) +63% . Invitae ( NVTA ) +59% . Allego ( ALLG ) +54% . Grove Collaborative ( GROV ) +52% . BioAtla ( BCAB ) +40% . The Trade Desk ( TTD ) +37% . Chicken Soup for the Soul Entert...

OLMA - Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q2 GAAP EPS of -$0.82 misses by $0.18 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $240.7 million. For further details see: Olema Pharmaceuticals GAAP EPS of -$0.82 misses b...
OLMA - Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancer Reported progress across OP-1250 clinical development program, including selection of the recommended Phase 2 dose, initiation of Phase 2 monotherapy enrollment, and...

OLMA - Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into...

OLMA - Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#x...
OLMA - LIFE, TBLT and XTLB among pre market gainers

Super Micro Computer ( SMCI ) +20% on better-than-expected Q4 prelim results. ToughBuilt Industries ( TBLT ) +16% . MoonLake Immunotherapeutics ( MLTX ) +14% . Visionary Education Technology Holdings ( VEDU ) +12% . Olema Pharmaceuti...

OLMA - Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Olema Pharmaceuticals' ( NASDAQ: OLMA ) OP-1250 to treat certain patients with breast cancer. Specifically, the FDA designation for OP-1250 is to treat ER-positive (ER+), human epid...

OLMA - Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the Company's novel, oral ...
Previous 10 Next 10